ORGANOGENESIS HOLDINGS INC (ORGO) Fundamental Analysis & Valuation

NASDAQ:ORGO • US68621F1021

2.67 USD
-0.04 (-1.48%)
At close: Mar 11, 2026
2.71 USD
+0.04 (+1.5%)
After Hours: 3/11/2026, 4:21:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ORGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall ORGO gets a fundamental rating of 5 out of 10. We evaluated ORGO against 519 industry peers in the Biotechnology industry. ORGO scores excellent on profitability, but there are some minor concerns on its financial health. ORGO has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. ORGO Profitability Analysis

1.1 Basic Checks

  • ORGO had positive earnings in the past year.
  • In the past year ORGO has reported a negative cash flow from operations.
  • ORGO had positive earnings in 4 of the past 5 years.
  • ORGO had a positive operating cash flow in 4 of the past 5 years.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • ORGO has a Return On Assets of 2.65%. This is amongst the best in the industry. ORGO outperforms 88.82% of its industry peers.
  • ORGO has a Return On Equity of 3.65%. This is amongst the best in the industry. ORGO outperforms 89.98% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.83%, ORGO belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • ORGO had an Average Return On Invested Capital over the past 3 years of 5.16%. This is significantly below the industry average of 19.44%.
  • The last Return On Invested Capital (8.83%) for ORGO is above the 3 year average (5.16%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROIC 8.83%
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • The Profit Margin of ORGO (2.81%) is better than 88.63% of its industry peers.
  • In the last couple of years the Profit Margin of ORGO has declined.
  • ORGO's Operating Margin of 9.90% is amongst the best of the industry. ORGO outperforms 90.56% of its industry peers.
  • In the last couple of years the Operating Margin of ORGO has grown nicely.
  • ORGO's Gross Margin of 75.62% is amongst the best of the industry. ORGO outperforms 83.43% of its industry peers.
  • In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
Industry RankSector Rank
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ORGO Health Analysis

2.1 Basic Checks

  • ORGO has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for ORGO has been increased compared to 1 year ago.
  • Compared to 5 years ago, ORGO has less shares outstanding
  • ORGO has a worse debt/assets ratio than last year.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ORGO has an Altman-Z score of 3.04. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
  • ORGO has a better Altman-Z score (3.04) than 66.86% of its industry peers.
  • ORGO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • ORGO's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. ORGO outperforms 43.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 3.04
ROIC/WACC1.03
WACC8.6%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 3.62 indicates that ORGO has no problem at all paying its short term obligations.
  • ORGO has a Current ratio of 3.62. This is comparable to the rest of the industry: ORGO outperforms 42.97% of its industry peers.
  • ORGO has a Quick Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • ORGO has a Quick ratio (3.32) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.32
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ORGO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.94% over the past year.
  • Measured over the past years, ORGO shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.72% on average per year.
  • ORGO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.04%.
  • ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.77% yearly.
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
  • Based on estimates for the next years, ORGO will show a small growth in Revenue. The Revenue will grow by 3.93% on average per year.
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. ORGO Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.27 indicates a reasonable valuation of ORGO.
  • Based on the Price/Earnings ratio, ORGO is valued cheaper than 97.30% of the companies in the same industry.
  • ORGO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.25.
  • ORGO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 10.27
Fwd PE N/A
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • 99.04% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.72
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • ORGO has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ORGO's earnings are expected to grow with 12.92% in the coming years.
PEG (NY)N/A
PEG (5Y)0.61
EPS Next 2Y12.92%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ORGO Dividend Analysis

5.1 Amount

  • No dividends for ORGO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORGO Fundamentals: All Metrics, Ratios and Statistics

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (3/11/2026, 4:21:04 PM)

After market: 2.71 +0.04 (+1.5%)

2.67

-0.04 (-1.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners54.15%
Inst Owner Change-0.51%
Ins Owners32.49%
Ins Owner Change1.22%
Market Cap343.47M
Revenue(TTM)564.17M
Net Income(TTM)15.85M
Analysts85
Price Target8.67 (224.72%)
Short Float %19.4%
Short Ratio15.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.05%
Min EPS beat(2)44.72%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)16.53%
Min EPS beat(4)-73%
Max EPS beat(4)167.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.19%
Min Revenue beat(2)10.3%
Max Revenue beat(2)28.08%
Revenue beat(4)2
Avg Revenue beat(4)6.94%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)28.08%
Revenue beat(8)6
Avg Revenue beat(8)7.04%
Revenue beat(12)7
Avg Revenue beat(12)4.32%
Revenue beat(16)7
Avg Revenue beat(16)2.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-111.11%
EPS NQ rev (3m)-111.11%
EPS NY rev (1m)-117.24%
EPS NY rev (3m)-117.24%
Revenue NQ rev (1m)-26.28%
Revenue NQ rev (3m)-26.28%
Revenue NY rev (1m)-13.79%
Revenue NY rev (3m)-13.79%
Valuation
Industry RankSector Rank
PE 10.27
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.87
EV/EBITDA 3.72
EPS(TTM)0.26
EY9.74%
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.39
BVpS3.37
TBVpS3.08
PEG (NY)N/A
PEG (5Y)0.61
Graham Number4.44
Profitability
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROCE 11.21%
ROIC 8.83%
ROICexc 10.88%
ROICexgc 12%
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
FCFM N/A
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ROICexc(3y)6.81%
ROICexc(5y)10.02%
ROICexgc(3y)7.75%
ROICexgc(5y)12.19%
ROCE(3y)6.54%
ROCE(5y)9.15%
ROICexgc growth 3Y14.91%
ROICexgc growth 5Y-14%
ROICexc growth 3Y18.93%
ROICexc growth 5Y-6.02%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
F-Score2
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.17
Cap/Depr 76.1%
Cap/Sales 2.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.32
Altman-Z 3.04
F-Score2
WACC8.6%
ROIC/WACC1.03
Cap/Depr(3y)97.86%
Cap/Depr(5y)180.1%
Cap/Sales(3y)3.4%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y159.64%
EBIT growth 3Y35.82%
EBIT growth 5Y15.91%
EBIT Next Year-3.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-685.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.56%
OCF growth 3YN/A
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 7 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.